DNA Biomed Solns (DNA) - Total Assets
Based on the latest financial reports, DNA Biomed Solns (DNA) holds total assets worth ILA100.00 Million ILA (≈ $268.10K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore DNA Biomed Solns (DNA) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
DNA Biomed Solns - Total Assets Trend (2005–2024)
This chart illustrates how DNA Biomed Solns's total assets have evolved over time, based on quarterly financial data. See net assets of DNA Biomed Solns for net asset value and shareholders' equity analysis.
DNA Biomed Solns - Asset Composition Analysis
Current Asset Composition (December 2024)
DNA Biomed Solns's total assets of ILA100.00 Million consist of 65.6% current assets and 34.4% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 65.5% |
| Accounts Receivable | ILA0.00 | 0.0% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how DNA Biomed Solns's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see DNA Biomed Solns market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DNA Biomed Solns's current assets represent 65.6% of total assets in 2024, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 65.5% of total assets in 2024, down from 76.6% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
DNA Biomed Solns Competitors by Total Assets
Key competitors of DNA Biomed Solns based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Merus BV
NASDAQ:MRUS
|
USA | $771.99 Million |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
China | CN¥3.01 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Starlake Bioscience Co Inc Zhaoqing Guangdong
SHG:600866
|
China | CN¥17.39 Billion |
DNA Biomed Solns - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 48.83 | 101.37 | 0.01 |
| Quick Ratio | 48.83 | 101.37 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA69.02 Million | ILA66.84 Million | ILA-9.47 Million |
DNA Biomed Solns - Advanced Valuation Insights
This section examines the relationship between DNA Biomed Solns's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.49 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | 29.3% |
| Total Assets | ILA104.28 Million |
| Market Capitalization | $34.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values DNA Biomed Solns's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: DNA Biomed Solns's assets grew by 29.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for DNA Biomed Solns (2005–2024)
The table below shows the annual total assets of DNA Biomed Solns from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA104.28 Million ≈ $279.57K |
+29.29% |
| 2023-12-31 | ILA80.66 Million ≈ $216.24K |
-1.62% |
| 2022-12-31 | ILA81.99 Million ≈ $219.81K |
+50.11% |
| 2021-12-31 | ILA54.62 Million ≈ $146.43K |
+195.33% |
| 2020-12-31 | ILA18.49 Million ≈ $49.58K |
-49.66% |
| 2019-12-31 | ILA36.73 Million ≈ $98.49K |
-54.49% |
| 2018-12-31 | ILA80.72 Million ≈ $216.39K |
+3.36% |
| 2017-12-31 | ILA78.09 Million ≈ $209.37K |
+104.57% |
| 2016-12-31 | ILA38.17 Million ≈ $102.34K |
+37.57% |
| 2015-12-31 | ILA27.75 Million ≈ $74.39K |
+43.63% |
| 2014-12-31 | ILA19.32 Million ≈ $51.80K |
-6.59% |
| 2013-12-31 | ILA20.68 Million ≈ $55.45K |
-2.43% |
| 2012-12-31 | ILA21.20 Million ≈ $56.84K |
+26.02% |
| 2011-12-31 | ILA16.82 Million ≈ $45.10K |
+74.24% |
| 2010-12-31 | ILA9.65 Million ≈ $25.88K |
+7813.93% |
| 2009-12-31 | ILA122.00K ≈ $327.08 |
-97.59% |
| 2008-12-31 | ILA5.07 Million ≈ $13.60K |
+48.35% |
| 2006-12-31 | ILA3.42 Million ≈ $9.17K |
-47.21% |
| 2005-12-31 | ILA6.48 Million ≈ $17.36K |
-- |
About DNA Biomed Solns
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physi… Read more